- The case series examines the use of sirolimus, an mTOR inhibitor, as an additional treatment for hyperinsulinemic hypoglycaemia (HH) in infants who don't respond to standard therapies.
- Four infants from two pediatric centers in Australia were treated with sirolimus, with their clinical responses and side effects tracked through chart reviews.
- Results showed sirolimus to be effective and mostly safe, leading to hospital discharges, but suggested a need for careful monitoring and lower dosing to mitigate risks, highlighting the necessity for more research on its use.